Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
— MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors
Cambridge, UK, April 14, 2026 – Mestag Therapeutics, a biotech company harnessing fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory disease, announced today that it has been selected to present a late‑breaking poster at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17–22, 2026 in San Diego, California.
